Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Sino Biopharmaceutical

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 7
Average round size
info
The average size of a deal this fund participated in
$250M
Portfolio companies 7
Rounds per year 0.26
Lead investments 1
Exits 2
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Manufacturing
  • Medical Device
  • Life Science
Summary

The company was established in Asia in Hong Kong. The main department of described Corporate Investor is located in the Hong Kong.

The usual cause for the fund is to invest in rounds with 2 partakers. Despite the Sino Biopharmaceutical, startups are often financed by Shenzhen Capital Group, TriWise Capital, CCB Capital. The meaningful sponsors for the fund in investment in the same round are Loyal Valley Capital.

Among the most popular portfolio startups of the fund, we may highlight Akeso Biopharma. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. Among the most popular fund investment industries, there are Biopharma, Biotechnology.

The important activity for fund was in 2019. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of more than 100 millions dollars.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Sino Biopharmaceutical:
Typical Co-investors
Sino Biopharmaceutical is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Sino Biopharmaceutical:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Even China, Jiangsu, Suzhou
Everbright Prestige Capital Beijing, Beijing, China
Fomocraft Ventures -
Morningside Technology Ventures China, Shanghai, Shanghai
Osprey Capital Illinois, United States, Wilmette
Rivington Capital Partners Houston, Texas, United States
Sony Music Entertainment New York, New York, United States
Toyo Engineering Chiba, Chiba Prefecture, Japan
Trentino Sviluppo -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Treadwell Therapeutics

Biotechnology
Health Care
Therapeutics
$91M18 Nov 2021 New York, New York, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sino Biopharmaceutical?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 7
Average round size 250M
Rounds per year 0.26
Peak activity year 2021
Lead investments 1
Exits 2
Group Appearance index 0.57

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Treadwell Therapeutics

Biotechnology
Health Care
Therapeutics
$91M18 Nov 2021 New York, New York, United States
Crunchbase icon

Content report

The following text will be sent to our editors: